[Reprogrammed M1 macrophages with inhibited STAT3, STAT6 and/or SMAD3 extends lifespan of mice with experimental...

Area of Science:

• Immunology
• Cancer Biology
• Cell Therapy

Background:

• Macrophages play a critical role in tumor immunity, with M1 and M2 phenotypes exhibiting distinct functions.
• Modulating macrophage polarization offers a potential therapeutic strategy for cancer treatment.
• Specific transcription factors like STAT3, STAT6, and SMAD regulate M2 macrophage polarization.

Purpose of the Study:

• To reprogram M1 macrophages by inhibiting M2 phenotype transcription factors (STAT3, STAT6, SMAD).
• To evaluate the impact of reprogrammed M1 macrophages on Ehrlich carcinoma (EC) growth in vitro and in vivo.
• To compare the anti-tumor efficacy of reprogrammed M1 macrophages against standard treatments.

Main Methods:

• Tumor growth models were established using EC cells in culture (in vitro) and intraperitoneal injection in mice (in vivo).
• M1 macrophages were reprogrammed by inhibiting STAT3, STAT6, and SMAD transcription factors.
• Macrophage phenotypes and anti-tumor effects were assessed in vitro and in vivo.

Main Results:

• M1 macrophages with inhibited STAT3/6-SMAD3 demonstrated significant anti-tumor effects in both in vitro and in vivo models.
• The anti-tumor efficacy of M1-STAT3/6-SMAD3 macrophages surpassed that of M1, M1-STAT3/6, M1-SMAD3 macrophages, and cisplatin.
• Inhibition of STAT3, STAT6, and/or SMAD3 in M1 macrophages effectively restricted tumor progression.

Conclusions:

• Reprogramming M1 macrophages by inhibiting STAT3, STAT6, and SMAD transcription factors is a viable strategy to restrict tumor growth.
• This approach holds promise for developing novel anti-tumor cell therapy technologies.
• Targeting these transcription factors offers a new avenue for cancer treatment development.